The Signal
Of the compounds marketed as “longevity supplements,” only four categories have meaningful human trial data behind them: NAD+ precursors, resveratrol, spermidine, and senolytics — and even within that shortlist, the results are messier than the marketing suggests.
NAD+ precursors have the clearest single-study win so far, resveratrol’s headline mechanism failed to hold up in the most rigorous recent meta-analysis, and spermidine’s best-designed trial came back null on its primary outcome. This guide walks through what the actual studies found, category by category, so you can decide what’s worth a spot in your stack and what’s still just promising mouse data.
Why This Matters After 40
Open a longevity podcast and you’ll hear the same five names on repeat: NMN, resveratrol, spermidine, fisetin, quercetin. Open PubMed and the picture looks different. According to PubMed, a 2023 review of NAD+-boosting compounds noted that roughly a dozen human clinical trials of NMN supplementation were underway at the time of writing — a real number, but a small one, especially against how ubiquitous these products have become on pharmacy shelves.
The underlying biology is often legitimate. The gap is between “acts on a validated aging pathway in a dish or a mouse” and “moves a measurable outcome in a randomized human trial.”
That gap is exactly what this guide tracks, compound by compound, so you can build the rest of your longevity protocol stack around what the trials actually show rather than what the label promises. If you’re in your 40s or 50s and already tracking biomarkers, this is the category where “data-driven” most often quietly slides into “marketing-driven” instead — the compounds themselves are real, the mechanisms are real, and the human confirmation is still catching up.
The Biology: What’s Actually Happening
Each of these four supplement categories targets a different piece of the aging process, and a building-maintenance analogy makes the differences easier to hold onto. NAD+ precursors (NMN, NR) resupply a resource that literally runs the repair crews — NAD+ is a co-substrate that hundreds of enzymes need to do their jobs, and its concentration in skin, blood, liver, muscle, and brain measurably declines with age.
Senolytics act like a demolition crew: they target “senescent” cells that have stopped dividing but refuse to die, instead sitting around secreting inflammatory signals that damage nearby healthy tissue. Spermidine works more like a recycling program, triggering autophagy — the process by which cells break down and reuse their own damaged components.
Resveratrol’s proposed mechanism is different again: it’s marketed as an activator of sirtuins, a family of proteins often described as the building’s maintenance managers, deciding where repair resources get allocated. That last mechanism is also the one with the shakiest human evidence, which is worth keeping in mind before the research section below.
It’s worth being explicit about what these compounds are not doing: none of them reverse the calendar. They’re targeting specific, well-characterized biological processes that happen to change with age — NAD+ availability, senescent cell accumulation, autophagy rate, and (allegedly) sirtuin activity — on the theory that intervening earlier in the process produces a healthier trajectory than waiting for the downstream disease to show up. That’s a reasonable hypothesis.
It’s also a different claim than “this pill makes you biologically younger,” which is the version that tends to make it into the marketing copy.
What the Research Actually Shows
NAD+ Precursors (NMN, NR)
The strongest single result in this category comes from a 2021 study published in Science (n=25, postmenopausal women who were overweight or obese with prediabetes). Over 10 weeks, participants who took 250 mg/day of NMN saw insulin-stimulated glucose disposal in skeletal muscle rise by roughly 25% (p<0.01), alongside increased insulin signaling activity, while the placebo group showed no change.
Body composition, fasting glucose, and liver fat didn’t budge in either group — the effect was specific to muscle insulin sensitivity, not a blanket metabolic overhaul.
A useful nuance sits inside that same paper’s discussion section: several controlled trials of nicotinamide riboside (NR), a different NAD+ precursor, failed to improve insulin sensitivity in middle-aged and older men. NMN and NR are often marketed as interchangeable, but the human data so far doesn’t support treating them that way — we cover that distinction in full in our dedicated NMN vs. NR comparison.
A 2023 review in the Journals of Gerontology (Freeberg et al.) reinforces the bigger-picture limitation: NAD+ precursors reliably raise NAD+ levels and appear safe and well-tolerated, but small sample sizes across the existing trials still limit how much can be concluded about downstream physiological benefits.
Resveratrol
A 2020 randomized, placebo-controlled trial published in the Journal of Bone and Mineral Research (the RESHAW trial) found that postmenopausal women taking 75 mg of resveratrol twice daily for 12 months saw improved bone mineral density in the lumbar spine and femoral neck, alongside a 7.24% reduction in a bone-resorption marker compared with placebo.
But resveratrol’s headline claim — that it activates sirtuins the way red wine enthusiasts have heard for two decades — doesn’t hold up well under closer inspection. A 2025 dose-response meta-analysis in the Journal of the Academy of Nutrition and Dietetics pooled 11 randomized controlled trials and found resveratrol supplementation produced no significant change in Sirt1 gene expression, protein expression, or serum levels overall.
A separate 2024 systematic review of resveratrol in older adults found real benefits when combined with exercise and some cognitive protection in Alzheimer’s patients, but no advantage over placebo in people with diabetes or peripheral artery disease. The net picture: resveratrol may do something useful in specific populations, but “it turns on your longevity genes” is not a claim the current human evidence supports.
Spermidine
The best-designed spermidine trial to date is also its most humbling result. The SmartAge trial, published in JAMA Network Open in 2022, followed 100 adults aged 60–90 with subjective cognitive decline for 12 months on 0.9 mg/day of spermidine from wheat-germ extract. The primary outcome — memory performance — showed no significant difference between the spermidine and placebo groups. Exploratory analyses hinted at possible benefits for inflammation and verbal memory, but the trial’s own primary endpoint came back null.
Worth noting: that 0.9 mg/day dose is far below what’s been tested for safety. A 2024 double-blind trial in Nutrition Research gave healthy older men up to 40 mg/day of high-purity spermidine for 28 days with no adverse events and only minimal changes in circulating polyamines — suggesting the body tightly regulates spermidine levels regardless of intake, and that most commercial wheat-germ extract supplements may simply be under-dosed relative to what’s been studied.
Senolytics (Fisetin, Quercetin, Dasatinib)
Senolytics are the newest and least-tested category here. Early human trials combining dasatinib and quercetin (D+Q) reduced senescent cell burden in the fat tissue of patients with diabetic kidney disease and improved physical function in patients with idiopathic pulmonary fibrosis, according to a 2021 review in Mechanisms of Ageing and Development. Those are genuinely promising results — but they come from small, disease-specific patient populations, not healthy adults taking a supplement for general longevity.
Fisetin trials in broader aging populations are still underway. A separate 2024 review in the Journal of Alzheimer’s Disease looked specifically at polyphenol senotherapeutics — quercetin, resveratrol, fisetin, and others — in Alzheimer’s disease and found the preclinical signal promising but concluded that in-human trials remain limited, with inconclusive findings, calling for more work on dosing and bioavailability before any of these compounds can be considered established senotherapeutics.
If you want the full breakdown of dosing protocols being studied and how fisetin compares to the D+Q combination, that’s the subject of our dedicated senolytics deep dive.
Honorable mentions
Two compounds outside the “big four” quietly have better evidence than their hype level suggests. A 2026 systematic review in Nutrition Reviews found that 5 of 6 studies on creatine and cognition in older adults reported a positive relationship, particularly for memory and attention — though the authors flagged mixed methodological quality and called for better-designed trials.
A 2024 systematic review in Nutrients synthesized 15 clinical trials on curcumin and healthy aging, reporting encouraging signals for cognitive function, inflammation, and muscle health in older adults, though optimal dosing is still unsettled.
The Protocol: What to Actually Do
1. Start with the human trial, not the mechanism
A compelling story about sirtuins or senescent cells is not the same as a result in people. Before adding anything to your stack, find out whether it’s been tested in a randomized human trial — and if it hasn’t, treat it as speculative, however elegant the biology.
2. Match your dose to the studied dose
The trials above used specific amounts for specific durations: 250 mg/day NMN over 10 weeks, 150 mg/day resveratrol (split into two 75 mg doses) over 12 months, and spermidine doses ranging from a modest 0.9 mg/day up to a safety-tested 40 mg/day. A different dose is functionally a different experiment — proprietary blends that don’t disclose exact amounts make it impossible to know if you’re anywhere near the tested range.
3. Pick one compound and one biomarker at a time
Stacking four unproven compounds at once makes it impossible to know which one is doing anything. Choose a single addition, pair it with one measurable marker relevant to its claimed mechanism (fasting insulin for NAD+ precursors, a bone density scan for resveratrol, inflammatory markers for spermidine), and test that marker before you start.
4. Budget for a null result
Based on the evidence above, expect roughly even odds that a given compound does nothing measurable for you specifically. That’s not a reason to avoid experimentation — it’s a reason to keep the experiment cheap, time-boxed, and easy to walk away from.
5. Re-test before you renew
Set a 6- to 12-month checkpoint. Re-run the biomarker you started with, compare it honestly against cost, and drop anything that isn’t earning its place in the budget.
6. Separate “generally safe” from “proven effective”
Several of the compounds above — NMN, spermidine, high-dose resveratrol — have decent human safety data even where efficacy data is thin. Safety and effectiveness are two different questions, and supplement marketing routinely blurs the two.
The Tech That Helps
None of this is worth much without a way to measure it. A standard longevity-relevant blood panel — fasting insulin, hs-CRP, and a lipid panel at minimum — gives you a real before-and-after baseline for most of the compounds discussed here, and most direct-to-consumer lab services now offer these without a doctor’s visit.
If cost is a concern, prioritize testing the single marker most tied to whatever you’re trying (fasting insulin for NAD+ precursors is the most directly evidence-backed pairing from the research above) rather than buying every panel available.
Epigenetic age tests have also become widely available direct-to-consumer, and they’re tempting to use as a single “did it work” scorecard. Treat them cautiously for this purpose: most weren’t designed or validated to detect a one-year supplement effect, and test-retest variability at that timescale can be large enough to swamp a genuine signal. They’re more useful as a long-term trend line than as a verdict on any single compound.
The Bottom Line
Right now, NAD+ precursors and creatine have the most convincing — if still narrow — human evidence behind them. Resveratrol’s marquee “activates longevity genes” claim doesn’t survive the most rigorous recent meta-analysis, even though it may still help specific outcomes like bone density in certain populations.
Spermidine is safe at studied doses but hasn’t yet beaten placebo on its flagship cognitive claim. Senolytics remain the most mechanistically exciting category, but the human evidence is still early and confined to sick populations, not healthy longevity-seekers.
None of this means skip supplements entirely — it means spend on the ones with a trial behind them, at the dose that trial used, and track a number to know if it’s working. For the full breakdown of protocols across every pillar, explore the full Longevity Protocols guide →
Which longevity supplement are you currently taking on faith rather than evidence — and would you drop it if a well-designed trial came back null?
💬COMMUNITY QUESTION : Which longevity supplement are you currently taking on faith rather than evidence — and would you drop it if a well-designed trial came back null?
Honestly, before you add anything from this list to your cart — grab the free ChronoBiohacker Quick-Start Guide first. It won’t tell you which supplement to buy, but it’ll help you get your baseline numbers in place so you actually know if whatever you try is doing something. → Get the guide
DISCLAIMER : This article summarizes published research for educational purposes — it isn’t medical advice and isn’t a recommendation to start any supplement. Talk to a doctor before adding anything here to your routine, especially if you take other medications or have an existing health condition.
LINKS :
